UBI Ubisoft Entertainment SA

Ubisoft Appoints Virginie Haas as Chief studios Operating Officer as Christine Burgess-Quémard Retires

Ubisoft Appoints Virginie Haas as Chief studios Operating Officer as Christine Burgess-Quémard Retires

Ubisoft Appoints Virginie Haas as Chief studios Operating Officer as Christine Burgess-Quémard Retires

Paris – August 31st, 2020 – Ubisoft today announced that Virginie Haas, currently a board member of the Company, is appointed Executive Director, Chief studios Operating Officer and joins Ubisoft’s Executive Committee, effective September 1, 2020. Virginie Haas succeeds Christine Burgess-Quémard who will retire by the end of this year after more than thirty successful years at Ubisoft.

Virginie Haas brings to Ubisoft 30+ years of experience in new technologies and IT services industry, combining leadership positions in both Corporate and start-up businesses globally.  She has been serving on the Company’s Board of Directors since 2017.

Yves Guillemot, Co-Founder and Chief Executive Officer, said: “I have worked closely with Virginie over the past three years, and I am delighted to welcome her to lead our production teams worldwide. She brings to the group proven leadership skills and broad experience in developing, transforming and managing fast-growing businesses. As a board member for the last 3 years, she is already familiar with our industry, our business model and with our culture. She has a strong expertise in the tech fundamentals driving our industry, notably including cloud computing, go-to-market services and digital transformation.”

Virginie Haas said: “It is an honor for me to join Ubisoft, succeeding Christine Burgess-Quémard and working with such talented and dedicated people around the world. I very much look forward to contributing to the next chapter.”

Christine Burgess-Quémard, a member of the Company’s Executive Committee, has been leading Ubisoft’s worldwide production efforts for more than two decades. She has been instrumental in the successful growth and development of Ubisoft, serving as one of the founding members who built it from a regional video game company to a world leader in interactive entertainment and services. Recognizing her contributions to and achievement in the video game industry, in 2018 Ms. Burgess-Quémard was honoured with the Women of the Year 2018 Award by the organization Women in Games.

Yves Guillemot, Co-Founder and Chief Executive Officer, said: “After an exemplary career at Ubisoft, we wish Christine Burgess-Quémard all the best in her retirement. She joined us at the very beginning of our journey and has contributed immensely to the development of our group worldwide, to the creation of a unique portfolio of highly respected brands in the videogame industry and the expansion of our international footprint. Christine is an outstanding leader, with deep values and true ethics, a role model for the new generation of women leaders in the creative and tech industry. Everyone at Ubisoft joins me today to thank her deeply for her invaluable contribution to the group. We will miss her dearly”. 

Note to Editors - Virginie Haas Biography

Virginie Haas brings Ubisoft 30+ years of experience in the field of new technologies and digital services. She spent a large part of her career at IBM, where she held various management positions. In 2006, she joined the Steering Committee of IBM France as Director of Operations, before becoming Vice President, Global Technology Services Sales. In 2010, she is appointed IBM’s Vice President of Worldwide Cloud Services Sales at Global level, driving a fast-growing expansion of the newly built IaaS business. In 2016, Virginie Haas moved to Shift Technology as Chief Revenue Officer. In 3 years, this Next-40 series C InsurTech scale-up offering AI-based SaaS solutions became a worldwide leader, with a global presence in more than 25 countries. Since September 2017, Virginie Haas has been a member of the board of Ubisoft, sitting on the Nomination and Compensation Committee since 2018.

About Ubisoft

Ubisoft is a leading creator, publisher and distributor of interactive entertainment and services, with a rich portfolio of world-renowned brands, including Assassin’s Creed®, Far Cry®, For Honor®, Just Dance®, Watch Dogs®, Tom Clancy’s video game series including Ghost Recon®, Rainbow Six® and The Division®. The teams throughout Ubisoft’s worldwide network of studios and business offices are committed to delivering original and memorable gaming experiences across all popular platforms, including consoles, mobile phones, tablets and PCs. For the 2019-20 fiscal year, Ubisoft generated net bookings of €1,534 million. To learn more, please visit:

© 2020 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.



Attachment

EN
31/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

Ubisoft Entertainment: 1 director

A director at Ubisoft Entertainment bought 100,000 shares at 4.114EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

 PRESS RELEASE

Information sur les droits de vote et les actions au 31 mars 2026

Information sur les droits de vote et les actions au 31 mars 2026  Le 8 avril 2026 Information relative au nombre total de droits de vote et d’actions composant le capital social Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext Paris Compartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 mars 2026(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) DateNombre total d’actions composant le capital so...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NKTR NEKTAR THERAPEUTICS
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
ACRS ACLARIS THERAPEUTICS INC.
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ORIC KEROS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PLTK SANA BIOTECHNOLOGY
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
EWTX PEPGEN INC
SLDB EDGEWISE THERAPEUTICS INC
DDI SOLID BIOSCIENCES INC
APGE DOUBLEDOWN INTERACTIVE CO LTD
EMBRAC B APOGEE THERAPEUTICS INC
DNTH EMBRACER GROUP AB
ORKA DIANTHUS THERAPEUTICS INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
IMA JADE BIOSCIENCES INC
IMAGENEBIO INC.
 PRESS RELEASE

Ubisoft Appoints New Leaders to Advance Its Creative Houses Operating ...

Ubisoft Appoints New Leaders to Advance Its Creative Houses Operating Model     PRESS RELEASE       Ubisoft Appoints New Leaders to Advance Its Creative Houses Operating ModelJulien Bares named General Manager of Creative Houses 3 and 5; Thomas Andrén named General Manager of the Creative Network PARIS – MARCH 17, 2026 – Today Ubisoft announced new leadership appointments supporting the rollout of its Creative Houses-led operating model, marking an important step in the company’s ongoing transformation. Julien Bares will join Ubisoft as General Manager of Creative Houses 3, focused on high...

 PRESS RELEASE

Ubisoft nomme de nouveaux dirigeants et poursuit la mise en place de s...

Ubisoft nomme de nouveaux dirigeants et poursuit la mise en place de son nouveau modèle opérationnel, fondé sur les Maisons de Création     COMMUNIQUÉ DE PRESSE        Ubisoft nomme de nouveaux dirigeants et poursuit la mise en place de son nouveau modèle opérationnel, fondé sur les Maisons de Création Julien Bares nommé General Manager des Maisons de Création 3 et 5 ; Thomas Andrén nommé General Manager du Creative Network PARIS – 17 MARS 2026 – Ubisoft annonce aujourd’hui de nouvelles nominations au sein de sa direction afin d’accélérer le déploiement du modèle opérationnel de ses Mai...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch